Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 10 versus QUILLICHEW ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 10 versus QUILLICHEW ER.
DYANAVEL XR 10 vs QUILLICHEW ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
None Documented
None Documented
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For QuilliChew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
QuilliChew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant